Carisma Therapeutics

3:45 PM - 4:00 PM (PDT), Monday, June 13, 2022
- Cell therapies have revolutionized how we treat cancer and made immunotherapy a household term; however, there remains an unmet need for improved treatment of solid tumors.
- Carisma is a biopharmaceutical company dedicated to developing a differentiated and proprietary cell therapy platform focused on engineered macrophages, cells that play a crucial role in both the innate and adaptive immune response. The first applications of the platform, developed in collaboration with the University of Pennsylvania, are autologous chimeric antigen receptor (CAR)-macrophages for the treatment of solid tumors and have the potential to transform the treatment of cancer and other serious illnesses. Carisma is headquartered in Philadelphia, PA.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Pennsylvania
Company HQ Country:
United States
Year Founded:
2016
Main Therapeutic Focus:
Lead Product in Development:
CT-0508
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Three – CAR-M products targeting HER2, Mesothelin, and PSMA expressing solid tumors